UK Markets closed

Shield Therapeutics plc (STX.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
6.50-0.10 (-1.52%)
At close: 04:35PM GMT
Full screen
Previous close6.60
Open6.51
Bid6.40 x 0
Ask6.60 x 0
Day's range6.40 - 6.60
52-week range5.52 - 38.00
Volume348,626
Avg. volume2,222,524
Market cap14.032M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Hardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital

    Hardman & Co ResearchHardman & Co Q&A on Shield Therapeutics (STX): Positioned for profitability with Viatris deal and its additional capital 23-Jan-2023 / 11:15 GMT/BST Analyst interview | Life SciencesQ&A on Shield Therapeutics (STX) | Positioned for profitability with Viatris deal and its additional capitaltive Shield Therapeutics (STX) is the topic of conversation when Dr Martin Hall joins DirectorsTalk Interviews.Martin summarises a number of announcements made by the company recently, expl

  • EQS Group

    Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability

    Hardman & Co Research Hardman & Co Research: Shield Therapeutics (STX) - Positioned for growth and profitability 13-Jan-2023 / 07:15 GMT/BSTHardman & Co Research on Shield Therapeutics (STX): Positioned for growth and profitabilityShield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awareness of the differentiating